Melatonin High Dose 150mg & Integrative Cancer Care

Melatonin is a naturally occurring hormone best known for regulating sleep, but at higher doses, it has shown promising support for individuals undergoing cancer treatment, especially radiation therapy. Our Melatonin 150mg formulation is designed for those following integrative or complementary cancer care protocols under medical supervision.

Note: This is a product used by providers with a specific dosage base on specific health needs.  It is not to be used for insomnia.

Why High Doses of Melatonin?

While low doses of melatonin (3 mg - 20 mg) are commonly used for sleep, research suggests that high-dose melatonin (often 150mg or higher) may offer additional benefits for people facing cancer:

• Radiation Protection: May help reduce damage to healthy cells during radiation by acting as a powerful antioxidant.
• Tumor Modulation: Some studies indicate melatonin may help slow tumor growth or improve how cancer cells respond to therapy.
• Sleep and Stress Support: Improves sleep quality, which is essential for recovery and immune function.
• Immune Enhancement: Supports the immune system, which is often compromised during cancer treatment.
• Synergistic with Treatment: When used under guidance, high-dose melatonin may enhance the effectiveness of conventional treatments.

Supervision of Use

Melatonin  HD 150mg is not a standard over-the-counter sleep aid. This dosage should be used under the direction of a provider as part of a broader integrative oncology protocol.

Who Can Benefit from Melatonin HD 150mg?

Melatonin 150mg is typically recommended for individuals who are:

• Undergoing radiation therapy and looking to minimize side effects
• Following an integrative cancer care plan
• Seeking non-toxic supportive therapies for cancer management
• Working with a provider knowledgeable in high dose melatonin protocols

Supplement Facts

Melatonin High Dose Research

Mills, E., Wu, P., Seely, D., & Guyatt, G. (2005). Melatonin in the treatment of cancer: A systematic review of randomized controlled trials and meta-analysis. Journal of Pineal Research, 39(4), 360–366.

Mediavilla, M. D., Sánchez-Barceló, E. J., Tan, D. X., Manchester, L., & Reiter, R. J. (2010). Basic mechanisms involved in the anti-cancer effects of melatonin. Current Medicinal Chemistry, 17(36), 4462–4481.

Govender, Jenelle, Ben Loos, and Anna-Mart Engelbrecht. "Melatonin: a protective role against doxorubicin-induced cardiotoxicity." Future Oncology 11.14 (2015): 2003-2006.

Mills, Edward, et al. "Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta analysis." Journal of pineal research 39.4 (2005): 360-366.

Lissoni, P., et al. "Increased survival time in brain glioblastomas by a radio neuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone." Oncology 53.1 (1996): 43-46.

Thomas, Charles R., Russel J. Reiter, and Terence S. Herman. "Melatonin: from basic research to cancer treatment clinics." Journal of Clinical Oncology 20.10 (2002): 2575-2601.

Srinivasan, Venkataramanujan, et al. "Therapeutic actions of melatonin in cancer: possible mechanisms." Integrative Cancer Therapies 7.3 (2008): 189-203.

Blask, David E., Leonard A. Sauer, and Robert T. Dauchy. "Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy." Current topics in medicinal chemistry 2.2 (2002): 113-132.

Conti, Ario, and Georges JM Maestroni. "The clinical neuroimmunotherapeutic role of melatonin in oncology." Journal of pineal research 19.3 (1995): 103-110.

Alonso González, Carolina, et al. "Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double strand DNA break repair." Journal of pineal research 58.2 (2015): 189-197.

Alonso-González, Carolina, et al. "Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis." Cancer letters 370.1 (2016): 145-152.

Loh, D., & Reiter, R. J. (2023). "Light, water, and melatonin: The synergistic regulation of phase separation in dementia." International Journal of Molecular Sciences, 24(6), 5835 https://doi.org/10.3390/ijms24065835

Tavakoli, Maryam. "Kidney protective effects of melatonin." Journal of Nephropharmacology 3.1 (2015).